Tumor necrosis factor Gene-Engineered J558 Tumor Cell-Released Exosomes Stimulate Tumor Antigen P1A-Specific CD8+ CTL responses and antitumor immunity

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 1, 2010, Pages 21-28

  Xie, Yufeng ^a   Bai, Ou ^a   Zhang, Haifeng ^a   Li, Wei ^a   Xiang, Jim ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Antitumor immunity; CTL; IFN ; IL 2; TNF ; Tumor exosome

Indexed keywords

CANCER VACCINE; GALECTIN; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; CANCER-TESTIS ANTIGEN P1A, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EXOSOME; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; ELECTRON MICROSCOPY; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; PROTEIN ENGINEERING; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EXOSOMES; FLOW CYTOMETRY; IMMUNIZATION; INTERFERON-GAMMA; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; MULTIPLE MYELOMA; PROTEIN ENGINEERING; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77649287195     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0714     Document Type: Article

References (44)

1. Thery C, Zitvogel L, Amigorena S. Exosomes: Composition, biogenesis, and function. Nat Rev Immunol 2002;2:569.
2. Denzer K, Kleijmeer MJ, Heijnen HF, et al. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000;113 (Pt 19):3365.
3. Thery C, Regnault A, Garin J, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein, hsc73. J Cell Biol 1999;147:599.
4. Escola JM, Kleijmeer MJ, Stoorvogel W, et al. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 1998;273:20121.
5. Andre F, Schartz NE, Chaput N, et al. Tumor-derived exosomes: A new source of tumor rejection antigens. Vaccine 2002;20 (Suppl 4):A28.
6. Kim JV, Latouche JB, Riviere I, et al. The ABCs of artificial antigen presentation. Nat Biotechnol 2004;22:403.
7. Chaput N, Schartz NE, Andre F, et al. Exosomes for immunotherapy of cancer. Adv Exp Med Biol 2003;532:215.
8. Andre F, Schartz NE, Movassagh M, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002;360:295.
9. Wolfers J, Lozier A, Raposo G, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001;7:297.
10. Altieri SL, Khan AN, Tomasi TB. Exosomes from plasma-cytoma cells as a tumor vaccine. J Immunother 2004;27:282.
11. Vincent-Schneider H, Stumptner-Cuvelette P, Lankar D, et al. Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T-cells. Int Immunol 2002;14: 713.
12. + CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol 2006;3:205.
13. Hsu DH, Paz P, Villaflor G, et al. Exosomes as a tumor vaccine: Enhancing potency through direct loading of antigenic peptides. J Immunother 2003;26:440.
14. Chaput N, Schartz NE, Andre F, et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naïve Tc1 lymphocytes leading to tumor rejection. J Immunol 2004;172:2137.
15. Cho JA, Yeo DJ, Son HY, et al. Exosomes: A new delivery system for tumor antigens in cancer immunotherapy. Int J Cancer 2005;114:613.
16. Pardoll DM. Cancer vaccines. Nat Med 1998;4:525.
17. Rodolfo M, Melani C, Zilocchi C, et al. IgG2a induced by interleukin (IL)-12-producing tumor cell vaccines, but not IgG1, induced by IL-4 vaccine is associated with the eradication of experimental metastases. Cancer Res 1998;58: 5812.
18. Yang Y, Xiu F, Cai Z, et al. Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. J Cancer Res Clin Oncol 2007;133:389.
19. +) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells. J Mol Med 2006; 84:1067.
20. + T-cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol 2003;171:2161.
21. Bai XF, Liu J, Li O, et al. Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T-lymphocytes. J Clin Invest 2003;111:1487.
22. Hock H, Dorsch M, Kunzendorf U, et al. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci U S A 1993; 90:2774.
23. Hock H, Dorsch M, Kunzendorf U, et al. Vaccinations with tumor cells genetically engineered to produce different cytokines: Effectivity not superior to a classical adjuvant. Cancer Res 1993;53:714.
24. Bai XF, Liu JQ, Joshi PS, et al. Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy. Cancer Res 2006;66:8241.
25. + T-cells by dendritic cell-derived exosomes. Nat Immunol 2002;3:1156.
26. Hao S, Bai O, Li F, et al. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology 2007;120:90.
27. + T-helper-antigen-presenting cells. J Immunol 2005;174:7497.
28. Lehmann BD, Paine MS, Brooks AM, et al. Senescence - associated exosome release from human prostate cancer cells. Cancer Res 2008;68:7864.
29. Luketic L, Delanghe J, Sobol PT, et al. Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL. J Immunol 2007;179:5024.
30. Fevrier B, Raposo G. Exosomes: Endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 2004; 16:415.
31. Hwang I, Shen X, Sprent J. Direct stimulation of naïve T-cells by membrane vesicles from antigen-presenting cells: Distinct roles for CD54 and B7 molecules. Proc Natl Acad Sci U S A 2003;100:6670.
32. Dai S, Wei D, Wu Z, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 2008;16:782.
33. Morse MA, Garst J, Osada T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small-cell lung cancer. J Transl Med 2005;3:9.
34. Kovar M, Boyman O, Shen X, et al. Direct stimulation of T-cells by membrane vesicles from antigen-presenting cells. Proc Natl Acad Sci U S A 2006;103:11671.
35. Zeng W, Chen G, Kajigaya S, et al. Gene-expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood 2004;103:325.
36. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009;9:581.
37. Xiu F, Cai Z, Yang Y, et al. Surface anchorage of super-antigen SEA promotes induction of specific antitumor immune response by tumor-derived exosomes. J Mol Med 2007;85:511.
38. Talmadge JE, Phillips H, Schneider M, et al. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res 1988;48:544.
39. Tracey KJ, Cerami A. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target. Annu Rev Med 1994;45: 491.
40. Brunner C, Seiderer J, Schlamp A, et al. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphateguanosine DNA drives T-cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 2000;165:6278.
41. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular, and in vivo level. FEBS Lett 1991;285:199.
42. Marr RA, Hitt M, Gauldie J, et al. A p75 tumor necrosis factor receptor-specific mutant of murine tumor necrosis factor alpha expressed from an adenovirus vector induces an antitumor response with reduced toxicity. Cancer Gene Ther 1999;6:465.
43. + monocytes through distinct pathways that activate NK-kappa B. J Immunol 2000;165:3647.
44. Brossart P, Zobywalski A, Grunebach F, et al. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res 2000;60:4485.